Ackermann et al[@bib1] recently reported the presence of severe endothelial injury and widespread pulmonary microthromboses accompanied with increased angiogenesis in lungs from deceased patients with coronavirus 2019 (COVID-19). These results support other recent publications from different centers reporting the presence of elevated coagulation markers[@bib2], [@bib3], [@bib4] and microthromboses in the lung and other organs of patients with COVID-19.[@bib5], [@bib6], [@bib7], [@bib8] Most recently, platelet activation and aggregation have been reported in patients with severe COVID-19,[@bib9] ^,^ [@bib10] but the triggers of these processes were not discussed.

The most potent trigger of platelet aggregation is platelet-activating factor (PAF), first discovered by Benvesiste in 1971.[@bib11] Demopoulos et al[@bib12] elucidated its structure as a glyceryl-ether lipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and described its semisynthetic preparation in 1979. PAF is produced by cells involved in host defense, and its biological actions bear similarities with COVID-19 disease manifestations.[@bib13] It was recently reported that platelets, via release of PAF, trigger perivascular mast cell activation, leading to inflammation.[@bib14] Moreover, mast cell degranulation associated with interstitial edema and immunothrombosis was recently reported in alveolar septa of deceased patients with COVID-19.[@bib15]

Mast cells are a rich source of PAF and are plentiful in the lungs,[@bib16] where they may contribute to COVID-19.[@bib17] We previously reported that levels of PAF were increased in allergic rhinitis[@bib18] and chronic urticaria,[@bib19] both of which involve activation of mast cells. Moreover, PAF appears to play a central role in inflammation.[@bib20] ^,^ [@bib21] In this context, innate immunity to COVID-19 appears to involve activated T cells and specific antibodies.[@bib22] ^,^ [@bib23] In addition, lung pathologic findings seen in severe acute respiratory syndrome (SARS) associated with COVID-19 are caused by a release of a storm of proinflammatory cytokines.[@bib24] ^,^ [@bib25] Mast cells are one of the richest sources of such cytokines, especially interleukin 6,[@bib26] ^,^ [@bib27] which has been implicated in COVID-19.[@bib28] Because mast cells are involved in lung diseases, it makes sense that such patients would be even more susceptible to pulmonary complications of COVID-19.[@bib29]

Given these findings, it would make sense to try to inhibit the action of PAF ([Fig. 1](#fig1){ref-type="fig"} ). A number of PAF inhibitors have been synthesized but are not available for clinical use,[@bib30], [@bib31], [@bib32] except for the histamine~1~ receptor antagonist rupatadine, which was developed to specifically exhibit anti-PAF activity.[@bib33] We reported that rupatadine also inhibits activation of human mast cells in response to PAF ([Fig. 1](#fig1){ref-type="fig"}).[@bib34] Rupatadine could, therefore, be repurposed for at least COVID-19 prophylaxis. Interestingly, certain natural flavonoids also have anti-PAF activity,[@bib35] ^,^ [@bib36] in addition to their having anti-inflammatory actions and the ability to block COVID binding to target cells.[@bib17] Figure 1Diagrammatic representation of the release of platelet-activating factor (PAF), along with interleukin (IL) 1β and IL-6, from mast cells activated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent formation of microembolisms in the lungs of patients with coronavirus 2019 leading to SARS. Treatment with the dual histamine~1~ and PAF-receptor antagonist rupatadine could limit or prevent this process.Figure 1
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